Skip to main content
    F

    Fennec Pharmaceuticals Inc (FENC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.76
    +1.14 (+9.81%)

    Market Cap: $410.25M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Fennec Pharmaceuticals Inc (FENC) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Fennec Pharmaceuticals (FENC) to earn $0.35 per share in the fiscal year ending Dec 31, 2026, on revenue of $74.59M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy120.0%
    Buy480.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 194.3% and revenue estimates rise 41.3%.

    Fiscal year ending Dec 31, 2026
    $0.35
    EPS consensus, revenue $74.59M
    Fiscal year ending Dec 31, 2027
    $1.03
    EPS consensus, revenue $105.38M
    Next report
    Mar 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.35$0.21 to $0.524$74.59M$73.97M to $75.10M3
    Dec 31, 2027$1.03$0.73 to $1.424$105.38M$99.60M to $110.57M5

    Quarterly Estimates

    The EPS consensus falls from $0.15 for the quarter ending Dec 31, 2026 to $0.12 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.15$0.09 to $0.248$21.93M$19.46M to $23.63M8
    Mar 31, 2027$0.12$0.11 to $0.132$22.47M$21.90M to $22.80M3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 8 upward and 4 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202641
    Fiscal year ending Dec 31, 202732
    Quarter ending Mar 31, 202711

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 6.1% from $0.33.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$0.35$0.32$0.32$0.32$0.33+4.0%
    Fiscal year ending Dec 31, 2027$1.03$0.95$0.95$0.95$0.95+8.5%
    Quarter ending Mar 31, 2027$0.12$0.11$0.11$0.11$0.11+9.1%

    Frequently Asked Questions About FENC

    What is the FENC stock forecast?

    Consensus analyst estimates put Fennec Pharmaceuticals's EPS at $0.35 for the fiscal year ending Dec 31, 2026, on revenue of $74.59M. The consensus rating from 5 analysts is Buy.

    How do analysts rate FENC stock?

    Of 5 analysts covering Fennec Pharmaceuticals, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from FENC next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.35, with estimates from $0.21 to $0.52 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.03, with estimates from $0.73 to $1.42 from 4 analysts.

    What revenue do analysts expect from Fennec Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $74.59M, with estimates from $73.97M to $75.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $105.38M, with estimates from $99.60M to $110.57M.

    How many analysts cover FENC?

    5 analysts rate Fennec Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.